Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

European Countries Should Join Forces To Lower Prices of Zolgensma & Kaftrio

Executive Summary

The Dutch HTA institute is calling for hefty discounts of 50% and 75% for Novartis’s gene therapy and Vertex’s cystic fibrosis product.

You may also be interested in...



Strength in Numbers: EU Cross-Country Drug Pricing Coalitions Join Forces

Two groups of smaller European countries have agreed to collaborate on tackling challenges relating to accessing expensive new medicines.

Biogen: BeNeLuxA Spinraza Talks “Collaborative And Constructive" But Not Without Challenges

Biogen, the first company to win a positive reimbursement decision from the BeNeLuxA groups, says the process was “constructive and collaborative.” However, differences in local laws mean there will initially be some differences in coverage.

Breakthrough Agreement On EU HTA Regulation “Falls Short”

The European Parliament and EU Council have reached an agreement on taking forward proposals for greater cooperation on health technology assessments.

Topics

UsernamePublicRestriction

Register

PS144346

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel